Literature DB >> 26193843

Osteogenesis imperfecta type III and hypogonadotropic hypogonadism result in severe bone loss: a case report.

Fabian Plachel1, Ursula Renner, Roland Kocijan, Christian Muschitz, Fritz Lomoschitz, Heinrich Resch.   

Abstract

We present the case of a 33-year-old male patient with multiple fractures and typical radiographical and clinical characteristics of osteogenesis imperfecta (OI) type III. Furthermore, the patient has suffered from hypogonadotropic hypogonadism since childhood. On the basis of antiresorptive therapy, no further fractures occurred within several years. Recently, recurrent nontraumatic fractures without bone healing were observed. Decreased bone mineral density was assessed by dual X-ray absorptiometry (DXA). High-resolution peripheral quantitative computed tomography (HR-pQCT) showed impaired trabecular bone structure. Due to recurrent fragility fractures and severe deterioration of bone structure, an osteoanabolic treatment with teriparatide was initiated to potentially stimulate fracture healing and to increase bone formation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26193843     DOI: 10.1007/s10354-015-0367-4

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  17 in total

Review 1.  Treatment of osteogenesis imperfecta in adults.

Authors:  Katarina Lindahl; Bente Langdahl; Östen Ljunggren; Andreas Kindmark
Journal:  Eur J Endocrinol       Date:  2014-04-23       Impact factor: 6.664

2.  GH in combination with bisphosphonate treatment in osteogenesis imperfecta.

Authors:  Franco Antoniazzi; Elena Monti; Giacomo Venturi; Roberto Franceschi; Francesco Doro; Davide Gatti; Giorgio Zamboni; Luciano Tatò
Journal:  Eur J Endocrinol       Date:  2010-06-30       Impact factor: 6.664

3.  The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. .

Authors:  C Wüster; R Abs; B A Bengtsson; H Bennmarker; U Feldt-Rasmussen; E Hernberg-Ståhl; J P Monson; B Westberg; P Wilton
Journal:  J Bone Miner Res       Date:  2001-02       Impact factor: 6.741

4.  Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials.

Authors:  Jannie D Hald; Evangelos Evangelou; Bente L Langdahl; Stuart H Ralston
Journal:  J Bone Miner Res       Date:  2015-05       Impact factor: 6.741

5.  Molecular screening of a large cohort of Moroccan patients with congenital hypopituitarism.

Authors:  Nabila Fritez; Marie-Laure Sobrier; Hinde Iraqi; Marie-Pierre Vié-Luton; Irène Netchine; Abdessamad El Annas; Jacques Pantel; Nathalie Collot; Sophie Rose; William Piterboth; Marie Legendre; Abdelmjid Chraibi; Serge Amselem; Abdelkrim Kadiri; Latifa Hilal
Journal:  Clin Endocrinol (Oxf)       Date:  2015-02-06       Impact factor: 3.478

6.  Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency.

Authors:  D J O'Halloran; A Tsatsoulis; R W Whitehouse; S J Holmes; J E Adams; S M Shalet
Journal:  J Clin Endocrinol Metab       Date:  1993-05       Impact factor: 5.958

7.  Congenital hypopituitarism: clinical, molecular and neuroradiological correlates.

Authors:  Ameeta Mehta; Peter C Hindmarsh; Hiten Mehta; James P G Turton; Isabelle Russell-Eggitt; David Taylor; W K Chong; Mehul T Dattani
Journal:  Clin Endocrinol (Oxf)       Date:  2009-03-06       Impact factor: 3.478

8.  Bone structure assessed by HR-pQCT, TBS and DXL in adult patients with different types of osteogenesis imperfecta.

Authors:  R Kocijan; C Muschitz; J Haschka; D Hans; A Nia; A Geroldinger; M Ardelt; R Wakolbinger; H Resch
Journal:  Osteoporos Int       Date:  2015-05-09       Impact factor: 4.507

9.  Evaluation of teriparatide treatment in adults with osteogenesis imperfecta.

Authors:  Eric S Orwoll; Jay Shapiro; Sandra Veith; Ying Wang; Jodi Lapidus; Chaim Vanek; Jan L Reeder; Tony M Keaveny; David C Lee; Mary A Mullins; Sandesh C S Nagamani; Brendan Lee
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

10.  Bone mineral density in early-onset hypogonadism and the effect of hormonal replacement.

Authors:  Jocely Vieira da Costa; Julia Fernanda Semmelmann Pereira-Lima; Miriam da Costa Oliveira
Journal:  J Clin Densitom       Date:  2004       Impact factor: 2.963

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.